Clinical Experience with the Use of Angiotensin Receptor Blockers in Patients with Cardiovascular, Cerebrovascular and Renal Diseases
Clinical Experience with the Use of Angiotensin Receptor Blockers in Patients with Cardiovascular, Cerebrovascular and Renal Diseases
复制标题
DOI：
10.2174/157488406776872532
复制
发表时间：
2006-01-01
影响因子：
3.2
通讯作者：
Chrysant, Steven G.
中科院分区：
文献类型：
--
作者：
Chrysant, Steven G.
血管紧张素II受体阻滞剂（ARB）是治疗高血压、心力衰竭、糖尿病肾病和脑卒中的有效和安全的药物。ARB通过选择性阻断血管紧张素II（Ang-II）亚型1（AT（1））受体以及很可能通过Ang-II刺激未占据的亚型2（AT（2））受体发挥作用。ARB在对血压、心力衰竭或糖尿病肾病的影响方面与其他抗高血压药物等效。就其中风保护作用而言，它们似乎上级于其他药物。它们通过双重作用发挥其中风保护作用，选择性地阻断Ang-II对AT（1）受体的作用，同时允许Ang-II刺激未占据的AT（2）受体。这种双重作用是ARB所独有的，可导致血管扩张和大脑缺血区血流量增加，从而改善和预防其扩展。ARB的所有这些行动都将在这次全面审查中讨论。
The Angiotensin II receptor blockers (ARBs) have been efficacious and safe drugs for the treatment of hypertension, heart failure, diabetic nephropathy and stroke from several short and long term clinical trials. The ARBs exert their effects through selective blockade of the angiotensin II (Ang-II) subtype 1 (AT(1)) receptor and quite possibly through stimulation by Ang-II of the unoccupied subtype 2 (AT(2)) receptor. The ARBs are equipotent to other antihypertensive drugs with respect to their effect on blood pressure, heart failure or diabetic nephropathy. They appear to be superior to the other drugs with respect to their stroke protective effect. They exert their stroke protective effect by a dual action, selectively blocking the action of Ang-II on the AT(1) receptors, while allowing Ang-II to stimulate the unoccupied AT(2) receptors. This dual action is unique to ARBs and results in vasodilation and increase in blood flow to the ischemic zone of the brain leading to improvement and prevention of its extension. All these actions of the ARBs will be discussed in this comprehensive review.